Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study

Anti-cancer Drugs
I GenvresseE Späth-Schwalbe

Abstract

In order to determine if age and comorbidity influence the tolerability of the cytoprotective agent amifostine, we compared side effects related to amifostine in patients > or = 70 years (group I) with patients < 70 years (group II). We evaluated 268 consecutive administrations of amifostine (119 in group I and 149 in group II, respectively), given i.v. at a dose of 740 mg/m(2) just before platinum-, taxol- or cyclophosphamide-based chemotherapy. Transient hypotension was the most common side effect occurring in association with amifostine. Decreases in systolic blood pressure > 20 mmHg were of similar frequency in both groups (27.1 versus 28.8% of amifostine infusions in group I and II, respectively). Hypotension did not result in medical sequelae in any of the patients. The amifostine infusion was interrupted 16 times in group I and 8 times in group II, respectively, mainly due to hypotension, but could be restarted after a few minutes in all patients except for three cases in group I. Patients in group II more often suffered from nausea/vomiting than in group II (20.8 versus 10.0% in group I). Other subjective symptoms (e.g. warmed, flushed sensation, sneezing, metallic taste, mouth dryness, dizziness and sleepiness) and hyp...Continue Reading

References

Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S WadlerC Runowicz
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerW Berry
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R M Bukowski
Oct 8, 1997·Cancer·R E Vestal
Mar 13, 1999·Seminars in Oncology Nursing·K G O'Connor

❮ Previous
Next ❯

Citations

Apr 4, 2008·Cell Biology and Toxicology·Alan R ParrishBruce D Hammock
Jan 22, 2004·Critical Reviews in Oncology/hematology·Sandro Pignata, Jan B Vermorken
Sep 18, 2012·Journal of Radiation Research·Chengjie ChenChangquan Ling
Oct 25, 2013·International Journal of Biological Sciences·Liren QianJianming Cai
Jul 19, 2014·Journal of Radiation Research·Sadahiro WatanabeYasuhiro Kanatani
Nov 11, 2003·Clinical Pharmacokinetics·Hans WildiersAllan T van Oosterom
Jan 1, 2004·Current Therapeutic Research, Clinical and Experimental·Sabri BarutcaZahit Bolaman
Feb 20, 2010·Free Radical Research·Liren QianJianming Cai
Jun 5, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tyler W LeBaronJan Slezak
Jun 4, 2020·Therapeutic Advances in Medical Oncology·ZhiYu DuanXiangMei Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Journal of Plastic Surgery and Hand Surgery
Megumi TakikawaTomoharu Kiyosawa
Clinical Journal of Oncology Nursing
Tracy K Gosselin, Beatrice Mautner
Free Radical Research
Yunhai ChuaiJianming Cai
Basic & Clinical Pharmacology & Toxicology
Zhitao JiangDapeng Jiang
© 2021 Meta ULC. All rights reserved